Premium
Reduction of the use of antimicrobial drugs following the rapid detection of Streptococcus agalactiae in the vagina at delivery by real‐time PCR assay
Author(s) -
PonceletJasserand E,
Forges F,
Varlet MN,
Chauleur C,
Seffert P,
Siani C,
Pozzetto B,
Ros A
Publication year - 2013
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/1471-0528.12138
Subject(s) - medicine , antimicrobial , streptococcus agalactiae , vagina , population , obstetrics , microbiology and biotechnology , surgery , streptococcus , biology , bacteria , genetics , environmental health
Objective To assess whether the determination of the presence of group B streptococci ( GBS ) in the vagina using a rapid polymerase chain reaction ( PCR ) assay at delivery was able to spare useless antimicrobial treatments, as compared with conventional culture at 34–38 weeks of gestation. Design Practical evaluation and prospective cost‐effectiveness analysis. Setting A university hospital in France. Population A cohort of 225 women in labour at the University‐Hospital of Saint‐Etienne. Methods Each woman had a conventional culture performed at 34–38 weeks of gestation. At the beginning of labour, two vaginal swabs were sampled for rapid PCR testing and culture. The decision to prescribe a prophylactic antimicrobial treatment or not was taken according to the result of the PCR test. A comparative cost‐effectiveness analysis of the two diagnostic strategies was carried out. Main outcome measures Number of women receiving inadequate prophylactic antimicrobial drugs following each testing strategy, costs of PCR testing and culture, frequency of vaginal GBS , and diagnostic performance of the PCR test at delivery. Results The percentage of unnecessarily treated women was significantly reduced using the rapid test versus conventional culture (4.5 and 13.6%, respectively; P < 0.001). The rate of vaginal GBS at delivery was 12.5%. The incremental cost‐effectiveness ratio ( ICER ) for each inadequate management avoided was €36 and €173 from the point of view of the healthcare system and hospital, respectively. Conclusions The PCR assay reduced the number of inadequate antimicrobial treatments aimed to prevent the early onset of GBS disease. However, this strategy generates extra costs that must be put into balance with its clinical benefits.